Frequently Asked Questions

DUPIXENT is the only dual inhibitor of IL-4 and IL‑13 signaling, two of the key sources of type 2 inflammation found in allergic fungal rhinosinusitis, asthma, atopic dermatitis, bullous pemphigoid, chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, eosinophilic esophagitis, and prurigo nodularis. The mechanism of dupilumab action has not been definitively established.^1-8

Watch a video on how DUPIXENT inhibits IL‑4 and IL‑13 signaling for the following conditions:

DUPIXENT is not a steroid. DUPIXENT is a biologic that inhibits signaling of IL‑4 and IL‑13, two of the key drivers of type 2 inflammation contributing to allergic fungal rhinosinusitis, asthma, atopic dermatitis, bullous pemphigoid, chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, eosinophilic esophagitis, and prurigo nodularis. The mechanism of dupilumab action has not been definitively established.^1-8

DUPIXENT is not an immunosuppressant and avoids broad immunosuppression.⁹

It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

Explore DUPIXENT’s mechanism of action for the following conditions:

The pre-filled syringe and pre-filled pen each come with their own set of specific instructions and guidelines for administration. After choosing your preferred method of treatment, you and your patient should go through the Instructions for Use to ensure each step is followed correctly.

For those who are indicated, it is recommended that children 12 years of age and older administer DUPIXENT under the supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.¹

Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use.¹

Advise patients to follow sharps disposal recommendations after administration of DUPIXENT. Patients and/or caregivers should read the appropriate Instructions for Use prior to injecting.¹

Download the full Instructions for Use

DUPIXENT is an injectable medicine that is administered by subcutaneous injection. You may decide whether patients self-administer DUPIXENT at home or you administer in office. DUPIXENT is intended for use under the guidance of a healthcare provider. A patient may self-inject DUPIXENT—or a caregiver may administer DUPIXENT—after training has been provided by a healthcare provider on proper subcutaneous injection technique using the pre-filled syringe or pen. In children 12 years of age and older, it is recommended that DUPIXENT be administered under the supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.¹

Explore dosing and administration:

DUPIXENT should be refrigerated between 36 °F  to 46 °F (2 °C to 8 °C) in the original carton to protect from light. If necessary, DUPIXENT may be kept at room temperature up to 77 °F (25 °C) for a maximum of 14 days. Do not store above 77 °F (25 °C). After removal from the refrigerator, DUPIXENT must be used within 14 days or discarded.¹

Do not expose DUPIXENT to heat or direct sunlight. Do NOT freeze. Do NOT shake.¹

For the 200 mg/1.14 mL (150 mg/mL) pre-filled pen or syringe, allow at least 30 minutes for DUPIXENT to reach room  temperature before injecting.¹

For the 300 mg/2 mL (175 mg/mL) pre-filled pen or syringe, allow at least 45 minutes for DUPIXENT to reach room temperature before injecting.¹

See information on preparation for use, storage, and handling of DUPIXENT:

If a weekly dose is missed, instruct the patient to administer the injection as soon as possible, and start a new weekly schedule from the date of the last administered dose.¹

If an every-2-week dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, instruct the patient to administer the dose, starting a new schedule based on this date.¹

If an every-4-week dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, instruct the patient to administer the dose, starting a new schedule based on this date.¹

Learn more about dosing instructions, schedules, and recommendations:

Administer the subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel. The upper arm can also be used if a caregiver administers the injection. Rotate the injection site with each injection. DO NOT inject DUPIXENT into skin that is tender, damaged, bruised, or scarred.¹

See the Instructions for Use for more details:

Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT. It is unknown if administration of live vaccines during DUPIXENT treatment will impact the safety or effectiveness of these vaccines. Limited data are available regarding coadministration of DUPIXENT with non-live vaccines.¹

Learn more about dosing for the following conditions:

No. Tuberculosis testing is not required with DUPIXENT according to the Prescribing Information.¹⁰

No, DUPIXENT does not have a boxed warning.¹

In the DUPIXENT pivotal clinical trials, the most common adverse reactions (incidence ≥1%) in patients with allergic fungal rhinosinusitis were injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.

In the DUPIXENT pivotal clinical trials, the most common adverse reactions (incidence ≥1%) in patients with asthma were injection site reactions, oropharyngeal pain, and eosinophilia.

In the DUPIXENT pivotal clinical trials, the most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis were injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia.

In the DUPIXENT pivotal clinical trials, the most common adverse reactions (incidence ≥2%) in patients with bullous pemphigoid were arthralgia, conjunctivitis, vision blurred, herpes viral infections, and keratitis.

In the DUPIXENT pivotal clinical trials, the most common adverse reactions (incidence ≥2%) in patients with chronic obstructive pulmonary disease were viral infection, headache, nasopharyngitis, back pain, diarrhea, arthralgia, urinary tract infection, local administration site reactions, rhinitis, eosinophilia, toothache, and gastritis.

In the DUPIXENT pivotal clinical trials, the most common adverse reactions (incidence ≥1%) in adult patients with chronic rhinosinusitis with nasal polyps were injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.

In the DUPIXENT pivotal clinical trials, the most common adverse reactions (incidence ≥2%) in patients with chronic spontaneous urticaria were injection site reactions.

In the DUPIXENT pivotal clinical trials, the most common adverse reactions (incidence ≥2%) in patients with eosinophilic esophagitis were injection site reactions, upper respiratory tract infections, arthralgia, and herpes viral infections.

In the DUPIXENT pivotal clinical trials, the most common adverse reactions (incidence ≥2%) in patients with prurigo nodularis were nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea.

Note: Select Important Safety Information: Warnings and Precautions—Hypersensitivity:

Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.¹ Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.

Explore the DUPIXENT safety profiles:

DUPIXENT does NOT have any known drug-to-drug interactions. DUPIXENT is NOT metabolized through the liver or excreted through the kidneys.¹

Explore the DUPIXENT safety profiles in each indication for the adverse drug reactions.

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information throughout.

The amount your patients pay for DUPIXENT will largely depend on whether they have insurance, the type of insurance they have, whether their insurance provider considers the medication to be preferred or not preferred, and whether they’ve met their deductible.

When filling out the DUPIXENT MyWay Enrollment Form, both you and your patient will be required to supply information, such as the patient’s insurance, diagnosis, and prescription. You can email or print the enrollment forms below.

A great place to start is with DUPIXENT MyWay, a patient support program that provides guidance with the insurance approval process as well as patient-centric education.

LOOK INTO DUPIXENT MyWay^®

You can use this guide to find out about the prior authorization request and appeal process for your patients appropriate for DUPIXENT.

NAVIGATING PRIOR
AUTHORIZATIONS AND
APPEALS FOR DUPIXENT

Overall, ~98% of commercially insured patients nationally are covered for DUPIXENT. By using the DUPIXENT formulary status tool, you can see which insurance plans offer coverage for DUPIXENT in your area. Contact the health plan or DUPIXENT MyWay to verify coverage for a specific patient. Coverage varies by type and plan.^11,a,b

^aFUN Documents, MMIT, and Policy Reporter as of September 2025.

^bCoverage varies by type and plan.

Use the DUPIXENT Formulary Status Tool:

Patients may be eligible for the DUPIXENT MyWay Copay Card if they have commercial health insurance, have a DUPIXENT prescription for an FDA-approved condition, and are a resident of the 50 United States, District of Columbia, Puerto Rico, Guam, or the USVI. The patient or caregiver must be aged 18 years or older to be eligible.

Eligible patients with commercial health insurance may pay as little as $0* in copay per fill of DUPIXENT® (dupilumab). Terms and conditions apply.

^*Subject to the program maximum per patient per calendar year. Approval is not guaranteed. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs, including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed, or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients’ out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms. Additional terms and conditions apply.

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT through benefits verification and assistance navigating the insurance process. It also offers financial assistance for eligible patients, one-on-one nursing support, and more. Our team can provide assistance during the insurance approval process. Support begins when your patients enroll in DUPIXENT MyWay.

Yes. DUPIXENT MyWay is committed to helping all eligible patients throughout the treatment process. At any time in the process, you or your patient can contact DUPIXENT MyWay for any needed support, such as help covering the cost of DUPIXENT or supplemental injection training. The DUPIXENT MyWay Nurse Educator will communicate directly with your patient and address any questions they may have about DUPIXENT, including the insurance process. While the insurance benefits for DUPIXENT are being confirmed, your patient will receive a welcome call from their DUPIXENT MyWay Nurse Educator.

The DUPIXENT MyWay Interim Access Program assists eligible, commercially insured patients who previously started DUPIXENT and are experiencing a specific, short-term lapse in therapy. It temporarily provides eligible patients DUPIXENT at no cost, subject to program terms and conditions. You or your patients can contact DUPIXENT MyWay at 1-844-DUPIXEN(T) (1-844-387-4936) to learn more.

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT through benefits verification and assistance navigating the insurance process. It also offers financial assistance for eligible patients, one-on-one nursing support, and more.

Overall, ~98% of commercially insured patients nationally are covered for DUPIXENT (FUN Documents, MMIT, and Policy Reporter as of September 2025). Coverage varies by type and plan.¹¹

With the DUPIXENT formulary status tool, you can see which insurance plans offer coverage for DUPIXENT in your area. Contact the health plan or DUPIXENT MyWay to verify coverage for a specific patient.

Use the DUPIXENT Formulary Status Tool:

If you have a current process for prescribing biologics delivered through a specialty pharmacy, you can utilize that process to get DUPIXENT approved for your patients.

Patients may be eligible for the DUPIXENT MyWay Copay Card if:

• They have commercial insurance
• They have a DUPIXENT prescription for an FDA-approved condition
• They are a resident of the 50 United States, the District of Columbia, Puerto Rico, Guam, or the USVI
• The patient or caregiver is aged 18 years or older

Eligible patients with commercial health insurance may pay as little as $0* in copay per fill of DUPIXENT^® (dupilumab). Terms and conditions apply.

^*Subject to the program maximum per patient per calendar year. Approval is not guaranteed. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs, including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed, or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients’ out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms. Additional terms and conditions apply.